TP53 and neoplasm: In summary, several different mechanisms that inhibit HIPK2 in tumors were identified, leading mainly to impairment of p53 response to drugs but also to induction of oncogenic pathways important in tumor progression, angiogenesis and chemoresistance such as Wnt/β-catenin and HIF-1 (Figure 2).